Texas: LabNow Lands $20 Million for AIDS Work
November 14, 2007
Austin-based LabNow Inc. has secured $20 million in investments to help the biotechnology firm establish a manufacturing line and conduct clinical trials on a device that can analyze a drop of blood. Though the technology can be used for many diagnostic purposes, the company is seeking to win Food and Drug Administration approval for monitoring CD4 lymphocytes, which are a key factor in assessing whether HIV drug treatments are working or need adjustments. LabNow CEO Rick Hawkins said he hopes to sell the device to nonprofits, universities, and businesses in Asia and Africa. The toaster-size device is a lower-cost alternative to current equipment and could transform the way HIV is managed, he said.
11.12.2007; Lilly Rockwell
Glaser Foundation Officials Call for Changes to Legislation That Would Reauthorize PEPFAR, Including Targets for Mother-to-Child HIV Transmission Prevention
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.